We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Is There is a Role of Prophylactic Therapy With Tamsulosin Before Extracorporeal Shock Wave Lithotripsy to Avoid Development of Steinstrasse ?

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00489723
Recruitment Status : Unknown
Verified June 2007 by HaEmek Medical Center, Israel.
Recruitment status was:  Recruiting
First Posted : June 21, 2007
Last Update Posted : June 21, 2007
Information provided by:

Study Description
Brief Summary:

The purpose of this study is to determine if there is a role of prophylactic therapy with tamsulosin prior extracorporeal shock wave lithotripsy to avoid development of steinstrasse. 150 persons that will go to Extracorporeal shock wave lithotripsy will randomize to 2 groups.

Group 1 -of 75 persons will recieve tamsulosin 0.4 mg x 1/d 2 days before the lithotripsy .

Group 2 - of 75 persons will not recieve tamsulosin. 48 hour after the ESWL all 2 group will take abdominal radiograph to evaluate the presence of steinstrasse.

Condition or disease Intervention/treatment
Kidney Stones Drug: tamsulosin 0.4mg

Study Design

Study Type : Observational
Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal
Time Perspective: Prospective
Study Start Date : May 2007

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts

Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   15 Years to 85 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • size of stone 1-2 cm

Exclusion Criteria:

  • ureteral stricture Presence of internal stent prior use of alfa bloker prior ESWL
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00489723

Contact: DORON PEREZ, M.D. +972-4-6495115 perez_do@clalit.org.il

Haemek medical center Recruiting
Afula, Israel, 18100
Contact: DORON PEREZ, M.D.    +972-4-6495115    perez_do@clalit.org.il   
Principal Investigator: doron perez, M.D.         
Sponsors and Collaborators
HaEmek Medical Center, Israel
Principal Investigator: doron perez Urology department: Haemek Medical Center
More Information

ClinicalTrials.gov Identifier: NCT00489723     History of Changes
Other Study ID Numbers: 0056-07-EMC
First Posted: June 21, 2007    Key Record Dates
Last Update Posted: June 21, 2007
Last Verified: June 2007

Keywords provided by HaEmek Medical Center, Israel:
size of stone 1-2 cm
Pt. with no use of alfa bloker prior ESWL
Pt. without internal stent

Additional relevant MeSH terms:
Kidney Calculi
Kidney Diseases
Urologic Diseases
Urinary Calculi
Pathological Conditions, Anatomical
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Urological Agents